Drug Approval | April 28, 2024
Zydus receives final approval from USFDA for Tretinoin Cream
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Natco Pharma intends to defend the matter accordingly
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The demand in Africa for COVID-19 vaccines has declined
Subscribe To Our Newsletter & Stay Updated
